COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19) [0.03%]
法国前瞻性多中心队列(PAPESCO-19)描述了癌症患者中新冠肺炎感染常常无症状
Ke Zhou,Jean-Luc Raoul,Audrey Blanc-Lapierre et al.
Ke Zhou et al.
Background: Cancer patients (CPs) are considered more vulnerable and as a high mortality group regarding COVID-19. In this analysis, we aimed to describe asymptomatic COVID (+) CPs and associated factors. ...
Corrigendum to Tumour seeding after a thoracic biopsy for renal cell carcinoma: a case report and a review of the literature [0.03%]
肾细胞癌胸部活检后肿瘤种植1例及文献复习的更正通知书
[This corrects the article DOI: 10.1177/11795549211022261.]. © The Author(s) 2022.
Impact of Upfront Chemotherapy on the Effect of Primary Tumour Resection for Asymptomatic Synchronous Colorectal Cancer With Unresectable Metastases: A Propensity-Score-Matched Cohort Analysis [0.03%]
新诊断无症状同步结直肠癌伴不可切除转移灶患者术前化疗对原发瘤切降效果影响的倾向性匹配队列研究
Lin Huang,Guixia Wei,Nan Chen et al.
Lin Huang et al.
Background: It is controversial whether primary tumour resection (PTR) and the sequencing of chemotherapy and PTR are associated with the survival of patients with incurable stage IV colorectal cancer. This study aimed to...
Pretreatment Inflammatory Markers Predict Outcomes and Prognosis in Colorectal Cancer Patients With Synchronous Liver Metastasis [0.03%]
术前炎症标志物可预测同步肝转移结直肠癌患者的结局和预后
Qingfang Li,Linyan Chen,Hongyu Jin et al.
Qingfang Li et al.
Introduction: Pretreatment inflammatory markers were applied to predict the prognosis of colorectal cancer. However, the role of these markers in predicting survival in patients with synchronous colorectal liver metastasi...
Body Mass Index and Diabetes Mellitus May Predict Poorer Overall Survival of Oral Squamous Cell Carcinoma Patients: A Retrospective Cohort From a Tertiary-Care Centre of a Resource-Limited Country [0.03%]
身体质量指数和糖尿病可能预示资源匮乏国家三级诊疗中心口腔鳞癌患者的总体生存率较差：一项回顾性队列研究
Yumna Adnan,Syed Muhammad Adnan Ali,Muhammad Sohail Awan et al.
Yumna Adnan et al.
Introduction: Oral squamous cell carcinoma (OSCC) is one of the highest-ranking cancers among both genders in Pakistan. Obesity is linked to a much higher risk for developing multiple cancer types. Individuals with Diabet...
No.253 Lymph Nodes Metastasis in Left-Sided Colorectal Cancer Liver Metastasis (CRLM) Patients: Incidence and Prognosis [0.03%]
左侧结直肠癌肝转移(CRLM)患者淋巴结转移的发病率及预后第253号
Jiang Chang,Yihao Mao,Qingyang Feng et al.
Jiang Chang et al.
Background: No.253 lymph node is the gateway to systemic metastasis for left-sided colorectal cancer. However, the value of D3 resection is still controversial. This study aimed to identify the incidence rate and prognost...
Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer [0.03%]
一线化疗后的Glasgow预后评分对晚期非小细胞肺癌患者的价值研究
Kristin Stokke,Marie Søfteland Sandvei,Bjørn Henning Grønberg et al.
Kristin Stokke et al.
Background: The Glasgow prognostic score (GPS) is an established inflammatory prognostic index in cancer patients. Most studies have only measured GPS at baseline (B-GPS). Effective cancer therapy may reduce inflammation,...
Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer [0.03%]
局部治疗联合一线表皮生长因子受体酪氨酸激酶抑制剂可提高表皮生长因子受体突变型转移性非小细胞肺癌患者的生存率
Xiaotong Lu,Jingbo Wang,Chunyu Wang et al.
Xiaotong Lu et al.
Background: EGFR tyrosine kinase inhibitor (TKI) is recommended as the first-line therapy for patients with EGFR-mutant metastatic non-small cell lung cancer (NSCLC). Yet, resistance often occurs in 1 year after therapy a...
Whole-Brain Radiotherapy Combined With Anlotinib for Multiple Brain Metastases From Non-small Cell Lung Cancer Without Targetable Driver Mutation: A Single-Arm, Phase II Study [0.03%]
用于无驱动基因突变非小细胞肺癌多发脑转移的全脑放疗联合安罗替尼治疗：单组二期临床研究
Jianjiang Liu,Jun Xu,Wanli Ye et al.
Jianjiang Liu et al.
Background: Existing evidence demonstrates that radiotherapy and antiangiogenic drugs have synergistic antitumour effects and may be a promising treatment option for patients with solid tumour. Thus, we performed a phase ...
Complement 4 Aids in the Prediction of Newly Diagnosed Multiple Myeloma Outcome in Patients [0.03%]
补体4有助于新诊断的多发性骨髓瘤患者预后预测
Lihua Zhang,Xiaosui Ling,Fan Li et al.
Lihua Zhang et al.
Background: A cure for the heterogeneous hematological malignancy multiple myeloma (MM) is yet to be developed. To date, the early risk factors associated with poor outcomes in MM have not been fully elucidated. Studies h...